Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose for iron deficiency in symptomatic atrial fibrillation
ACTRN12620000285954Phase 4Recruiting
- Sponsor
- University of Adelaide
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Atrial fibrillation (AFib) and iron deficiency anemia (IDA) comparing Ferric carboxymaltose with Placebo (2 arms). Primary endpoints: Change in VO2 peak and Change in ventilatory efficiency. Started Jul 2020; status: recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
Atrial fibrillation (AFib)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ACTRN12620000285954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000285954.